Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Smart nanodevice combined tumor-specific vector with cellular microenvironment-triggered property for highly effective antiglioma therapy.

Shao K, Ding N, Huang S, Ren S, Zhang Y, Kuang Y, Guo Y, Ma H, An S, Li Y, Jiang C.

ACS Nano. 2014 Feb 25;8(2):1191-203. doi: 10.1021/nn406285x. Epub 2014 Jan 13.

PMID:
24397286
2.

Functionalized nanoscale micelles with brain targeting ability and intercellular microenvironment biosensitivity for anti-intracranial infection applications.

Shao K, Zhang Y, Ding N, Huang S, Wu J, Li J, Yang C, Leng Q, Ye L, Lou J, Zhu L, Jiang C.

Adv Healthc Mater. 2015 Jan 28;4(2):291-300. doi: 10.1002/adhm.201400214. Epub 2014 Aug 13.

PMID:
25124929
3.

Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.

Gao W, Xiang B, Meng TT, Liu F, Qi XR.

Biomaterials. 2013 May;34(16):4137-49. doi: 10.1016/j.biomaterials.2013.02.014. Epub 2013 Mar 1.

PMID:
23453200
4.

T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.

Kuang Y, An S, Guo Y, Huang S, Shao K, Liu Y, Li J, Ma H, Jiang C.

Int J Pharm. 2013 Sep 15;454(1):11-20. doi: 10.1016/j.ijpharm.2013.07.019. Epub 2013 Jul 15.

PMID:
23867728
5.
6.

Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.

Huang S, Li J, Han L, Liu S, Ma H, Huang R, Jiang C.

Biomaterials. 2011 Oct;32(28):6832-8. doi: 10.1016/j.biomaterials.2011.05.064. Epub 2011 Jun 22.

PMID:
21700333
7.

Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.

Huang S, Shao K, Liu Y, Kuang Y, Li J, An S, Guo Y, Ma H, Jiang C.

ACS Nano. 2013 Mar 26;7(3):2860-71. doi: 10.1021/nn400548g. Epub 2013 Mar 12.

PMID:
23451830
8.

A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.

Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS.

Mol Pharm. 2011 Oct 3;8(5):1559-72. doi: 10.1021/mp200161f. Epub 2011 Jun 30.

9.

Functional nanoparticles in targeting glioma diagnosis and therapies.

Li M, Deng H, Peng H, Wang Q.

J Nanosci Nanotechnol. 2014 Jan;14(1):415-32. Review.

PMID:
24730272
10.

Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.

Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, Tirughana R, Ghoda LY, Barish ME, Brown CE, Najbauer J, Potter PM, Portnow J, Synold TW, Aboody KS.

Stem Cells Transl Med. 2013 Dec;2(12):983-92. doi: 10.5966/sctm.2012-0177. Epub 2013 Oct 28.

11.

Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.

Fan CH, Ting CY, Liu HL, Huang CY, Hsieh HY, Yen TC, Wei KC, Yeh CK.

Biomaterials. 2013 Mar;34(8):2142-55. doi: 10.1016/j.biomaterials.2012.11.048. Epub 2012 Dec 14.

PMID:
23246066
12.

Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.

Yamini B, Yu X, Pytel P, Galanopoulos N, Rawlani V, Veerapong J, Bickenbach K, Weichselbaum RR.

Clin Cancer Res. 2007 Oct 15;13(20):6217-23.

13.

Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays.

Gao H, Yang Z, Zhang S, Pang Z, Liu Q, Jiang X.

Acta Biomater. 2014 Feb;10(2):858-67. doi: 10.1016/j.actbio.2013.11.003. Epub 2013 Nov 15.

PMID:
24239900
14.

Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma.

Wang Y, Wang K, Zhao J, Liu X, Bu J, Yan X, Huang R.

J Am Chem Soc. 2013 Mar 27;135(12):4799-804. doi: 10.1021/ja312221g. Epub 2013 Mar 15.

PMID:
23495667
15.

Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy.

Miao D, Jiang M, Liu Z, Gu G, Hu Q, Kang T, Song Q, Yao L, Li W, Gao X, Sun M, Chen J.

Mol Pharm. 2014 Jan 6;11(1):90-101. doi: 10.1021/mp400189j. Epub 2013 Dec 2.

PMID:
24295590
16.

Tumor antigens in astrocytic gliomas.

Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD.

Glia. 1995 Nov;15(3):244-56. Review.

PMID:
8586461
17.

Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.

Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.

Neurosurgery. 2009 Sep;65(3):610-24; discussion 624. doi: 10.1227/01.NEU.0000350227.61132.A7.

PMID:
19687708
18.

Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.

Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, Van Rooijen N, Lowenstein PR, Castro MG.

Clin Cancer Res. 2009 Oct 1;15(19):6113-27. doi: 10.1158/1078-0432.CCR-09-1087. Epub 2009 Sep 29.

19.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
20.

Suppressing the malignant phenotypes of glioma cells by lentiviral delivery of small hairpin RNA targeting hypoxia-inducible factor-1α.

Dong CG, Wu WK, Feng SY, Yu J, Shao JF, He GM.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2323-32. eCollection 2013.

Items per page

Supplemental Content

Write to the Help Desk